MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - FRA:MED - DE0006595101 - Common Stock
3.66 EUR
+0.12 (+3.39%)
Taking everything into account, MED scores 6 out of 10 in our fundamental rating. MED was compared to 27 industry peers in the Health Care Providers & Services industry. MED scores excellent on profitability, but there are concerns on its financial health. MED may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
MED had positive earnings in the past year.
In the past year MED had a positive cash flow from operations.
In multiple years MED reported negative net income over the last 5 years.
Each year in the past 5 years MED had a positive operating cash flow.
1.2 Ratios
MED has a better Return On Assets (3.76%) than 70.37% of its industry peers.
Looking at the Return On Equity, with a value of 14.64%, MED is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
MED has a better Return On Invested Capital (6.72%) than 74.07% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MED is below the industry average of 6.04%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(6.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.76% | ||
| ROE | 14.64% | ||
| ROIC | 6.72% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
Looking at the Profit Margin, with a value of 4.34%, MED is in the better half of the industry, outperforming 74.07% of the companies in the same industry.
In the last couple of years the Profit Margin of MED has grown nicely.
MED has a better Operating Margin (8.17%) than 70.37% of its industry peers.
MED's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 83.90%, MED belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
In the last couple of years the Gross Margin of MED has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.17% | ||
| PM (TTM) | 4.34% | ||
| GM | 83.9% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, MED has about the same amount of shares outstanding.
Compared to 5 years ago, MED has about the same amount of shares outstanding.
The debt/assets ratio for MED has been reduced compared to a year ago.
2.2 Solvency
MED has an Altman-Z score of 1.52. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
MED has a worse Altman-Z score (1.52) than 62.96% of its industry peers.
MED has a debt to FCF ratio of 10.50. This is a negative value and a sign of low solvency as MED would need 10.50 years to pay back of all of its debts.
MED's Debt to FCF ratio of 10.50 is on the low side compared to the rest of the industry. MED is outperformed by 62.96% of its industry peers.
A Debt/Equity ratio of 1.84 is on the high side and indicates that MED has dependencies on debt financing.
MED's Debt to Equity ratio of 1.84 is on the low side compared to the rest of the industry. MED is outperformed by 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | 10.5 | ||
| Altman-Z | 1.52 |
ROIC/WACC1.43
WACC4.71%
2.3 Liquidity
A Current Ratio of 1.82 indicates that MED should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.82, MED belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
MED has a Quick Ratio of 1.78. This is a normal value and indicates that MED is financially healthy and should not expect problems in meeting its short term obligations.
MED has a better Quick ratio (1.78) than 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 327.10% over the past year.
MED shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 20.79% yearly.
Looking at the last year, MED shows a small growth in Revenue. The Revenue has grown by 1.64% in the last year.
The Revenue has been growing slightly by 2.19% on average over the past years.
EPS 1Y (TTM)327.1%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%395.24%
Revenue 1Y (TTM)1.64%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%8.62%
3.2 Future
Based on estimates for the next years, MED will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.85% on average per year.
MED is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.80% yearly.
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MED is valuated cheaply with a Price/Earnings ratio of 5.15.
Based on the Price/Earnings ratio, MED is valued cheaper than 100.00% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.51. MED is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 6.77, which indicates a rather cheap valuation of MED.
Based on the Price/Forward Earnings ratio, MED is valued cheaply inside the industry as 100.00% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of MED to the average of the S&P500 Index (22.53), we can say MED is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.15 | ||
| Fwd PE | 6.77 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MED is valued cheaper than 96.30% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of MED indicates a rather cheap valuation: MED is cheaper than 85.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.01 | ||
| EV/EBITDA | 3.17 |
4.3 Compensation for Growth
MED's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MED has a very decent profitability rating, which may justify a higher PE ratio.
MED's earnings are expected to grow with 13.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.1
PEG (5Y)0.25
EPS Next 2Y14.23%
EPS Next 3Y13.85%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.08%.
Compared to an average industry Dividend Yield of 2.55, MED has a dividend in line with its industry peers.
With a Dividend Yield of 1.08, MED pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.08% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y14.23%
EPS Next 3Y13.85%
FRA:MED (11/3/2025, 7:00:00 PM)
3.66
+0.12 (+3.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.54%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap173.85M
Revenue(TTM)781.85M
Net Income(TTM)33.96M
Analysts83.33
Price Target4.79 (30.87%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.08% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)26.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.15 | ||
| Fwd PE | 6.77 | ||
| P/S | 0.22 | ||
| P/FCF | 4.01 | ||
| P/OCF | 1.87 | ||
| P/B | 0.75 | ||
| P/tB | 0.84 | ||
| EV/EBITDA | 3.17 |
EPS(TTM)0.71
EY19.4%
EPS(NY)0.54
Fwd EY14.76%
FCF(TTM)0.91
FCFY24.95%
OCF(TTM)1.96
OCFY53.61%
SpS16.46
BVpS4.88
TBVpS4.37
PEG (NY)0.1
PEG (5Y)0.25
Graham Number8.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.76% | ||
| ROE | 14.64% | ||
| ROCE | 8.66% | ||
| ROIC | 6.72% | ||
| ROICexc | 8.86% | ||
| ROICexgc | 9.27% | ||
| OM | 8.17% | ||
| PM (TTM) | 4.34% | ||
| GM | 83.9% | ||
| FCFM | 5.55% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.87
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.84 | ||
| Debt/FCF | 10.5 | ||
| Debt/EBITDA | 3.69 | ||
| Cap/Depr | 96.31% | ||
| Cap/Sales | 6.37% | ||
| Interest Coverage | 2.92 | ||
| Cash Conversion | 80.6% | ||
| Profit Quality | 127.75% | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 1.52 |
F-Score8
WACC4.71%
ROIC/WACC1.43
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)327.1%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%395.24%
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue 1Y (TTM)1.64%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%8.62%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y377.48%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y195.08%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.79%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
What is the valuation status for MED stock?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
What is the profitability of MED stock?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 5.15 and the Price/Book (PB) ratio is 0.75.
What is the earnings growth outlook for MEDICLIN AG?
The Earnings per Share (EPS) of MEDICLIN AG (MED.DE) is expected to grow by 52.44% in the next year.